At its meeting on 15 July 2024, the Transparency Council adopted opinion No. 109/2024 on the inclusion in reimbursement of medicines containing the active substance filgrastim in the indications: neutropenic fever (infection in the course of neutropenia), congenital neutropenia, acquired neutropenia
Publication on the list of opinions on active substances for off-label indications >>